title: Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
authors.affiliation: Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, Australia Damian.Harding@uhb.nhs.uk.
authors.forename: Damian J
authors.initials: DJ
authors.lastname: Harding
authors.affiliation: Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Gerry
authors.initials: G
authors.lastname: MacQuillan
authors.affiliation: Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Howman
authors.affiliation: Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Bastian
authors.initials: B
authors.lastname: de Boer
authors.affiliation: Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Leon
authors.initials: L
authors.lastname: Adams
authors.affiliation: Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Andrew
authors.initials: A
authors.lastname: Mitchell
authors.affiliation: Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, Australia.
authors.forename: Gary
authors.initials: G
authors.lastname: Jeffrey
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069439:Dasatinib / Q000008:administration & dosage*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000201:enzymology / Q000601:surgery; D016031:Liver Transplantation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib